PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34363593-5	2022	Newer agents, such as SY-5609, a selective CDK7 inhibitor, have also shown promising results in early clinical trials.	SY-5609	22-29	cyclin dependent kinase 7	Homo sapiens	43-47
34726887-0	2022	Discovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7.	SY-5609	13-20	cyclin-dependent kinase 7	Mus musculus	60-64
34726887-2	2022	This report describes the discovery of SY-5609, a highly potent (sub-nM CDK7 Kd) and selective, orally available inhibitor of CDK7 that entered the clinic in 2020 (ClinicalTrials.gov Identifier: NCT04247126).	SY-5609	39-46	cyclin-dependent kinase 7	Mus musculus	72-76
34726887-2	2022	This report describes the discovery of SY-5609, a highly potent (sub-nM CDK7 Kd) and selective, orally available inhibitor of CDK7 that entered the clinic in 2020 (ClinicalTrials.gov Identifier: NCT04247126).	SY-5609	39-46	cyclin-dependent kinase 7	Mus musculus	126-130
34726887-5	2022	The development candidate SY-5609 displays potent inhibition of CDK7 in cells and demonstrates strong efficacy in mouse xenograft models when dosed as low as 2 mg/kg.	SY-5609	26-33	cyclin-dependent kinase 7	Mus musculus	64-68